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Background: The guidelines established by the National Comprehensive Cancer Network do not describe
mucinous histology as a clinical factor that should influence the therapeutic algorithm. However, previous studies
show conflicting results regarding the prognosis of colorectal mucinous adenocarcinoma. In this study, we
described the clinicopathological features of mucinous adenocarcinoma in Japan, to identify optimal therapeutic
strategies.
Methods: 144 patients with mucinous and 2673 with non-mucinous adenocarcinomas who underwent primary
resection in two major centers in Yokohama, Japan were retrospectively evaluated for clinicopathological features
and treatment factors. A multivariate analysis for overall survival followed by the comparison of overall survival
using Cox proportional hazard model were performed.
Results: Patients with mucinous adenocarcinoma had larger primary lesions, higher preoperative CEA levels, a
deeper depth of invasion, higher rates of nodal and distant metastasis, and more metastatic sites. A multivariate
analysis for overall survival revealed a mucinous histology to be an independent prognostic factor. In the subgroup
analysis stratified by stage, Patients diagnosed as StageIII and IV disease had a worse survival in mucinous
adenocarcinoma than non-mucinous, while survival did not differ significantly in patients diagnosed as Stage0-II
disease. In StageIII, local recurrence in rectal cases and peritoneal dissemination were more frequently observed in
patients with a mucinous histology.
Conclusions: Our study indentified that mucinous adenocarcinoma was associated with a worse survival compared
with non-mucinous in patients with StageIII and IV disease. In rectal StageIII disease with mucinous histology,
additional therapy to control local recurrence followed by surgical resection may be a strategical alternative. Further
molecular investigations considering genetic features of mucinous histology will lead to drug development and
better management of peritoneal metastasis
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Colorectal cancer is the third most common cancer and
the fourth most frequent cause of cancer death world-
wide [1]. Mucinous adenocarcinoma (MA) is diagnosed
when more than 50% of the tumor comprises a mucin-
ous pattern upon histological examination [2]. MA
makes up 6 to 20% of all colorectal cancers [3-8], and
differs from non-mucinous adenocarcinoma (NMA)
with regard to its clinicopathological characteristics, dis-
tinct genetic profiles, and pathogenic pathways [9-12].
The prognostic significance of MA is controversial. In
previous studies, mucinous histology was reported not
to be an independent prognostic factor for survival
[13,14]. The guidelines established by the National Com-
prehensive Cancer Network (NCCN) do not describe
mucinous histology as a clinical factor that should influ-
ence the therapeutic algorithm [15,16]. However, in
some studies, it is reported that MA is associated with
worse clinicopathological characteristics [17-19] and a
poorer prognosis than NMA [5,17,20-23].
The lack of a consensus may be the result of the low
ratio of MA to all colorectal cancers and the limited de-
tection power to clarify the differences between MA and
NMA.
We conducted a retrospective analysis of patients with
colorectal cancer at two major centers to identify the
clinicopathological features of MA, and also investigated
the recurrence to establish an optimal therapeutic strat-
egy for MA.Methods
Patients
The data from 2,817 patients with colorectal cancer in
two major centers, Kanagawa Cancer Center and Yoko-
hama City University Medical Center, between 2001 and
2010 were investigated. Written informed consent was
obtained from the patient for publication of this report
and any accompanying images. All patients initially
underwent resection of a primary lesion followed by ad-
juvant chemotherapy when diagnosed as stage III dis-
ease. In tumor, node metastases (TNM) stage T3 to T4,
lower-rectal cases, total mesorectal excision (TME) and
lateral node dissection were routinely performed at ini-
tial resection. No patients were treated with neo- or ad-
juvant radiation therapy.
The analyzed patients were diagnosed with MA,
defined as tumors with more than 50% of the tumor vol-
ume comprising mucin, or with NMA, defined as
tumors without any mucinous features, or with a less
than 50% mucinous component [2]. Patients diagnosed
with signet ring cell carcinoma, undifferentiated carcin-
oma, and other histological types were excluded from
the analysis.The covariates included in the study were gender, age,
location of the tumor, size of the primary tumor, pre-
operative serum carcinoembryonic antigen (CEA) level,
depth of invasion, lymph node metastasis, distant metas-
tasis, operating facility, and histological type. The patho-
logical tumor status was coded using the TNM
classification system [24]. The use of adjuvant chemo-
therapy for patients with curative resection, as well as
additional therapy (chemotherapy and/or surgery) for re-
current and non-curative cases were also recorded.
In the analysis of the survival rates, all cases were
divided into 3 groups, that is, patients without any me-
tastases (stage 0 to II [24]), patients with regional lymph
node metastasis but without distant metastasis (stage
III), and patients with distant metastasis (stage IV).
Statistical analysis
The two groups of patients (MA and NMA) were com-
pared using 2 × 2 tables for binary factors using the χ2-
test, or Fisher’s exact test where appropriate. Overall
survival was calculated from the date of surgery for the
primary lesion until death from any cause, or was cen-
sored at the last follow-up visit. Survival data were ana-
lyzed using the Kaplan-Meier method. A comparison of
survival curves was carried out using the log-rank test.
The prognostic significance was analyzed by multivariate
Cox proportional hazard models. P-values< 0.05 were
considered statistically significant, and all P-values cor-
respond to two-sided significance tests.
Results
Of the 2,817 colorectal cancer patients, MA accounted
for 5.1% (144) of the colorectal cancer cases. The distri-
bution of the patients’ characteristics is shown in Table 1.
The distribution for gender, age, and location of MA
was similar to that of NMA. The patients with MA had
significantly larger primary lesions, higher preoperative
serum CEA levels, deeper invasion, higher nodal and
distant metastasis rates, and a larger number of meta-
static sites compared to the patients with NMA.
Table 2 shows the distribution of treatment factors, in-
cluding the curability of the first surgery, rate of adju-
vant chemotherapy, chemotherapy for advanced or
recurrent cases, and additional surgery for liver and lung
metastasis. For these factors, there were no significant
differences between the MA and NMA groups. Unlike
western countries, neo- or adjuvant radiation therapy for
patients with stage II and III disease is not commonly
performed in Japan.
To clarify the prognostic factors for colorectal cancer,
univariate and multivariate analysis were carried out. Mu-
cinous histology was noted to be one of the independent
prognostic factors for overall survival in univariate and
multivariate analysis (Tables 3 and 4). The 5-year relative
Table 1 Comparison of clinicopathological characteristics
in non-mucinous and mucinous adenocarcinoma
Characteristics NMA MA P-value





< 65 1,183 57




Size, cm < 0.001
< 5 1,715 59









T1, T2 979 13
















≧ 2 86 5
aStaging of tumor (T), nodes (N), and metastases (M) [24]; NMA, non-mucinous
adenocarcinoma; MA, mucinous adenocarcinoma.
Table 2 Comparison of treatment factors in
non-mucinous and mucinous adenocarcinoma
Treatment factors NMA MA P-value




surgery in rectal cancer




dissection in rectal cancer





















n = 123 n = 5 0.179
Yes 33 0
No 90 5
NMA, non-mucinous adenocarcinoma; MA, mucinous adenocarcinoma.
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nificantly worse than that of the NMA patients (73.8%),
with a median follow-up of 52 months (range 1 to 128
months) (Figure 1).
We next divided all cases into 3 groups (stage 0 to II,
stage III, and stage IV) to compare the overall survival in
each group. There were no significant differences in 5-year
survival in stage 0 to II based on the histological status
(MA: 88.5% vs. NMA: 91.0%, P=0.099) (Figure 2).However, in stage III (MA: 47.3% vs. NMA: 70.5%, P
< 0.001) (Figure 3) and stage IV (MA: 5.4% vs. NMA:
23.8%, P< 0.001) (Figure 4), the MA patients had a signifi-
cantly worse survival rate than the NMA patients.
The recurrence pattern in stage III was analyzed
(Table 5). The number of patients with any recurrence
in the MA and NMA groups was 17 (31.4%) and 182
(23.5%), respectively. The rate of liver metastasis, distant
lymph node metastasis, lung metastasis, and other site
recurrence was similar between the two groups. Periton-
eal dissemination (7.4% vs. 2.3%, P= 0.049), and local re-
currence (9.2% vs. 2.3%, P= 0.013) were more frequently
observed in the MA group. All of the locally recurrent
cases in the MA group were rectal cases.
The treatment factors were compared in stage IV dis-
ease (Table 6). However, the curability of the first resec-
tion, first regimen of chemotherapy, and the rate of
additional resection did not differ significantly between
the MA and NMA groups.
Table 3 Univariate analysis of overall survival in
colorectal adenocarcinoma
Variables HR (95% CI) P-value
Gender 0.004
Female 1.0
Male 1.349 (1.098, 1.656)
Age, years 0.049
< 65 1.0
≧ 65 1.217 (1.001, 1.480)
Location 0.049
Colon 1.0
Rectum 1.212 (1.000, 1.468)
Size, cm < 0.001
< 5 1.0

























Center B 2.365 (1.943, 2.878)
Histological type < 0.001
NMA 1.0
MA 2.614 (1.905, 3.585)
aStaging of tumor (T), nodes (N), and metastases (M) [24]; HR, hazard ratio; CI,
confidence interval; NMA, non-mucinous adenocarcinoma; MA, mucinous
adenocarcinoma.
Table 4 Multivariate Cox proportional hazards analysis of
overall survival in colorectal adenocarcinoma
Variables HR (95% CI) P-value
Gender 0.020
Female 1.0
Male 1.278 (1.040, 1.572)
Age, years 0.007
< 65 1.0
≧ 65 1.317 (1.078, 1.608)
Location 0.020
Colon 1.0
Rectum 1.267 (1.038, 1.547)
Size, cm 0.112
< 5 1.0





≧ 5.0 1.483 (1.203, 1.828)
Depth of invasiona < 0.001
T1, T2 1.0




















MA 2.226 (1.618, 3.062)
aStaging of tumor (T), nodes (N), and metastases (M) [24]; HR, hazard ratio; CI,
confidence interval; NMA, non-mucinous adenocarcinoma; MA, mucinous
adenocarcinoma.
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In this study, the data from 2,817 colorectal cancer
patients who underwent surgery in two major medical
centers in Yokohama city, Japan, were analyzed. In these
2,817 patients, the incidence of MA was 5.1%, which gen-
erally corresponds to the rate in other Asian countries, as
reported by Chew (6.0% from Singapore) [3] and Safaee
(8.5% from Iran) [6]. Other studies from Western coun-
tries described that the proportion of MA ranged from 11to 20% [4,5,7,8], which is higher than the rate for Asian
countries. This disparity may reflect the differences in geo-
graphic, ethnic and dietary factors.
In the analysis of the patients’ characteristics, the MA
group had worse clinical factors, including larger pri-
mary lesions, deeper invasion, higher rates of nodal and
distant metastasis, and a larger number of metastatic
sites compared to the NMA group. The previous reports
showed that younger patients, larger tumors, higher
Figure 1 The 5-year relative survival rate of patients with
mucinous adenocarcinoma (52.2%) was significantly worse
than those with non-mucinous adenocarcinoma (73.8%) as
determined by the log-rank test (P< 0.001). 5yOS, 5-year overall
survival.
Figure 3 The 5-year overall survival of patients with stage III
non-mucinous adenocarcinoma and mucinous adenocarcinoma.
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sis were correlated with MA histology when compared
to NMA histology [17-19], which was mostly in agree-
ment with our results.
The reason why MA patients have worse characteristics
than NMA patients is not fully understood. Sugarbaker etFigure 2 The 5-year overall survival of patients with stage I or
stage II non-mucinous adenocarcinoma and mucinous
adenocarcinoma.al. demonstrated that the more malignant characteristics
of MA may be partly due to the production of mucus
under pressure, which allows the MA cells to gain access
to the peritoneal cavity. Moreover, the fluid produced by
MA is taken up by the lymphatic system, which might help
to promote tumor spread into regional lymph nodes [25].
It remains unclear whether MA adversely affects sur-
vival in colorectal cancer patients. In some studies, MAFigure 4 The 5-year overall survival of patients with stage IV
non-mucinous adenocarcinoma and mucinous adenocarcinoma.
Table 5 The comparison of recurrent pattern in patients
with stage III disease
Recurrent pattern NMA MA P-value
(n = 774) (n = 54)
Liver metastasis 80 (10.3%) 4 (7.4%) 0.643
Peritoneal metastasis 18 (2.3%) 4 (7.4%) 0.049
Distant lymph node metastasis 30 (3.8%) 1 (1.8%) 0.715
Lung metastasis 60 (7.7%) 4 (7.4%) 1.000
Local recurrence 18 (2.3%) 5 (9.2%) 0.013
Other site recurrence 16 (2.0%) 3 (5.5%) 0.121
NMA, non-mucinous adenocarcinoma; MA, mucinous adenocarcinoma.
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[5,17,20-23], while others have found no such evidence
[13,14,26]. Both the American Joint Committee on Can-
cer and the College of American Pathologists consider
that the MA subtype has not been proven to be a statis-
tically significant prognostic factor [14,27]. The contra-
dictions in the various studies may be explained by the
geographical and racial variations in the epidemiology of
colorectal cancer [28,29], disparities in the criteria for
defining MA [22,30], and insufficient sample sizes to dis-
close any differences. In this study, we compared the
relative survival rate of MA and NMA patients in a rela-
tively large number of patients, and revealed that the
MA patients had significantly worse survival than the
NMA patients. Furthermore, multivariate analysis
demonstrated that MA histology is an independent
prognostic factor.
Based on our findings, we also performed an investiga-
tion to establish an optimal therapeutic strategy for MA.
To exclude the bias caused by stage, which is related to
the status of lymph node metastasis and distant metastasis,Table 6 Comparison of treatment factors in patients with
stage IV disease
Treatment factors NMA MA P-value
(n = 349) (n = 28)
Curability of first surgery 0.353
Complete 96 (27.5%) 10 (35.7%)
Incomplete 253 (72.5%) 18 (64.3%)
Regimen of first chemotherapy 0.362
OXA-based 25 (7.1%) 3 (10.7%)
IRI-based 18 (5.1%) 3 (10.7%)
5-FU intravenously 43 (12.3%) 4 (14.2%)
5-FU orally 36 (10.3%) 4 (14.2%)
Additional resection
Liver resection 75 (21.4%) 3 (10.7%) 0.228
Lung resection 10 (2.8%) 0 (0.0%) 1.000
OXA, oxaliplatin; IRI, irinotecan; 5-FU, 5-fluolouracil; NMA, non-mucinous
adenocarcinoma; MA, mucinous adenocarcinoma.we divided all cases into three subgroups and analyzed the
relative survival rate in each group. Consequently, the
prognosis of patients with MA was similar to that of
patients with NMA in stage I/II, whereas it was signifi-
cantly worse for MA patients in both stage III and stage
IV. Some of the above-mentioned literature supports the
relatively worse survival of MA patients when the subjects
are limited to stage III and stage IV disease [8,18,21],
which is consistent with our results. According to these
results, we speculated that the worse survival of stage III
and IV may contribute to the relatively poor overall prog-
nosis of the MA cases.
In the analysis of the recurrence pattern of stage III
disease, the incidence of local recurrence and peritoneal
metastasis was significantly higher in patients with MA
than in those with NMA. In addition, all cases of local
recurrence in the MA group were in patients with rectal
disease. Differences in the rates of liver, lung, and distant
lymph node metastases were not statistically significant.
In stage IV disease, we compared the treatment fac-
tors, including the curability of the first resection, first
chemotherapeutic regimen, and the need for additional
resection (liver and lung resection). This analysis
revealed that equivalent treatments were performed for
both MA and NMA patients.
Our results indicate that better management of the local
and peritoneal recurrence of stage III disease may improve
the survival of MA patients. In terms of local control, pre-
vious studies have shown that the difference in survival be-
tween MA and NMA patients was mainly related to
tumors with a rectal location [18], because MA cases are
more likely to be locally recurrent [31], which supports
our present results. Green et al. pointed out that the
lymphatic drainage of the pelvis is more extensive and var-
ied compared with that of the colon [5].
In the NCCN guidelines for treatment of rectal cancer
[16], it is recommended to perform pre- or postoperative
radiation therapy for patients with T3 to T4, or N1 to
N2 disease. However, In Japan, Sugihara et al. showed
that the five-year overall survival and the five-year lo-
cally controlling ratio in patients with T3 to T4 rectal
cancer treated by TME plus lateral node dissection, was
79.7% and 92.0% respectively [32]. Consequently, TME
and lateral node dissection is considered a standard ther-
apy for T3 to T4 rectal cancer, and neo- or adjuvant ra-
diation therapy is not commonly selected in Japan.
Considering our result, the application of pre- or post-
operative radiation therapy [33-36] may be a strategy to
prevent the development of local recurrence in MA
cases.
We also found that peritoneal metastasis was a significant
site of recurrence for MA in stage III disease. Metastasis to
the peritoneum is regarded to be a fatal manifestation of
gastrointestinal cancer, and is associated with a median
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sensitivity to chemotherapy, previous reports have demon-
strated that a mucinous histology generally predicts a
reduced response to a 5-FU-, oxaliplatin-, and irinotecan-
based regimen [39,40].
It is well known that there are several molecular path-
ways involving oncogene (for example KRAS) and the sup-
pressor gene in colorectal carcinogenesis [41], and
cetuximab is an established drug used for downstream
blocking of the EGFR-KRAS pathway. However, according
to Hanski et al., MA histology is characterized by a high
frequency of KRAS mutations, and a high frequency of
microsatellite instability [9], suggesting that MA histology
generally has drug-resistant properties of cetuximab. It is
also revealed that MA has different molecular alterations
and genetic subtypes to NMA [42]. Detailed molecular
and genetic analyses to detect specific pathways of MA
will help to develop new systemic chemotherapy, which is
necessary to improve peritoneal metastasis and overall sur-
vival in patients with MA.Conclusion
Our study indentified MA histology as an independ-
ent prognostic factor, and revealed that MA was
associated with worse survival compared with NMA
in patients with stage III and IV disease. The ability
of MA to disseminate and infiltrate more aggressively
than NMA appears to be responsible, at least in part,
for the higher rate of failure in stage III and IV,
which are the main reasons for the overall poorer
prognosis of patients with MA. Controlling local re-
currence and managing peritoneal metastasis are ne-
cessary to improve the overall survival in patients
with MA.
Besides considering radiation therapy after TME and
radical lymph node dissection for locally advanced rectal
cases, further investigations focusing on the genetic and
molecular characteristics of MA, will help better man-
agement of MA histology.
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